Delivery Order SPE2DB20D2104-SPE2DB22FR46D
- Not listed
- This federal contract award is for the delivery of Lamictal XR 200 mg tablets to the Defense Logistics Agency (DLA), a major procurement agency within the U.S. Department of Defense. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distribution company. The contract, worth $11,026.16, is a Firm Fixed Price Delivery Order with a completion date of November 2, 2023. It was awarded on November 1, 2023 and does not...
- This federal contract award is for the delivery of Lamictal XR 300mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $5,147.56, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999, serves as the...
- This federal contract award is for the delivery of LAMICTAL XR 300 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distribution company. The contract has a ceiling value of $27,717.99 and is a Firm Fixed Price Delivery Order contract that runs through November 20, 2023. This award is not associated with a set-aside program,...
- This federal contract award is for the delivery of Lamictal XR 200 mg tablets to the Defense Logistics Agency (DLA), a Defense agency. The prime contractor is Amerisourcebergen Drug Corp, a for-profit subsidiary of Amerisourcebergen Corporation that specializes in pharmaceutical distribution and medical supply services for government agencies, particularly the Department of Defense. The contract is a firm-fixed price delivery order valued at $5,162.19, with a period of performance through...
- This federal contract award is for the delivery of LAMICTAL XR 250 MG TABLET 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider that is a critical vendor for federal government agencies, particularly within military and veterans' healthcare systems. The contract has a ceiling value of $3,369.38 and is a Delivery Order contract with a Firm Fixed Price...
- This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide Lamictal XR 50 mg tablets. The $3,990.19 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00, which runs through November 2026. This IDC enables Amerisourcebergen to efficiently deliver a comprehensive range of pharmaceutical products and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $20,539.31, is for the delivery of Lamictal XR 300 mg tablets to support defense and civilian medical programs. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by the parent company, Cencora, Inc., doing business as AmerisourceBergen. This IDC, valued at up to...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Lamictal XR 50 mg tablets. The contract, valued at $20,981.38, is a delivery order with a firm fixed price. It does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is a for-profit organization registered in the System for Award...
- This federal contract award is for the delivery of LAMICTAL XR 100 MG TABLET 30S to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $34,560.36 and a completion date of November 15, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
- This federal contract award is for the delivery of Lamictal XR 300 mg tablets to the Defense Logistics Agency (DLA). The $11,618.10 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of September 27, 2022. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that has established itself as a key vendor for federal healthcare programs, particularly within military and...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FR46DDelivery Order
This federal contract award is for the delivery of Lamictal XR 300 mg tablets to the Defense Logistics Agency (DLA). The $2,775.56 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor registered in the System for Award Management (SAM.gov). The contract is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, and test kits, to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 1/10/22 |